Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Erika Richtig(Medical University of Graz), Giuseppe Palmieri(University of Sassari), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Miguel F. Sanmamed(Clinica Universidad de Navarra), Célèste Lebbé(Inserm), Ignacio Melero(University of Oxford), Maria Teresa Fierro(University of Turin), Virginia Ferraresi(Cancer Institute (WIA)), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Evaristo Maiello(Casa Sollievo della Sofferenza), Domenico Mallardo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Hildur Helgadóttir(Karolinska University Hospital), Michele Guida(Istituto Tumori Bari), Francesco Spagnolo(Martin University), Paola Queirolo, Marcello Curvietto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Sabino De Placido, Diana Giannarelli(Agostino Gemelli University Polyclinic), Reinhard Dummer(University Hospital of Zurich), Alessandro Marco Minisini, Helen Gogas(National and Kapodistrian University of Athens), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Gonzales Cao(Hospital Universitario Dexeus), Marco Tucci(Prostate Cancer UK)
Journal of Clinical Oncology
September 1, 2022
Cited by 231


Related Papers